Bexion Pharmaceuticals to Present New Findings at 2025 ASCO Annual Meeting

Bexion Pharmaceuticals to Present at ASCO 2025

Bexion Pharmaceuticals, Inc., a pioneering clinical-stage biopharmaceutical company, has announced that it will present two important abstracts at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This prestigious event will take place from May 30 to June 3, 2025, in Chicago, Illinois.

The abstracts focus on Bexion's leading investigational product, BXQ-350, which is a novel biologic therapy designed to treat solid tumor cancers and address chemotherapy-induced peripheral neuropathy (CIPN). The acceptance of these abstracts highlights the significance of Bexion's research in the oncology field, reinforcing its commitment to improving treatment options for patients.

Abstract Details

First Abstract:

Title: Effect of BXQ-350, a novel sphingolipid metabolism modulator, on neuronal environments through modulation of gene pathways
Abstract Number: e24058
Authors: Michael Gazda, Tariq Arshad, Jim Beach, Nikhil Wilkins, Adam Creighbaum, Timothy Stephens
Session Title: Publication Only - Symptom Science and Palliative Care

Second Abstract:

Title: A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma
Abstract Number: e14044
Authors: Tariq Arshad, Michael Gazda, Jim Beach, Kathleen Dorris, Margot Lazow, Trent Hummel, Richard Curry III, Adam Creighbaum
Session Title: Publication Only - Central Nervous System Tumors

The details of these abstracts are available in the ASCO digital program, providing attendees with insights into Bexion's ongoing research and potential breakthroughs in cancer treatment.

About BXQ-350

BXQ-350 is Bexion’s lead drug candidate, representing a first-in-class biologic that combines a multifunctional sphingolipid activator protein called Saposin C with a phospholipid. Clinical trials have demonstrated a robust safety profile, with promising signs of effectiveness against various solid tumors. Moreover, BXQ-350 is also being studied for its potential benefits in treating CIPN, a debilitating condition frequently experienced by cancer patients receiving chemotherapy, particularly oxaliplatin.

Company Profile

Bexion Pharmaceuticals is on the frontline of developing innovative biological therapies aimed at solid tumors and CIPN. The company has a strategic focus on providing solutions for patients with unmet medical needs and is exploring broader applications for its therapies in various cancers and neuropathic pain disorders. Bexion has successfully completed enrollment for its open-label Phase 1b/2 study, assessing BXQ-350 in combination with standard treatments, and has also finalized enrollment for a proof-of-concept trial aimed at treating CIPN.

With the acceptance of these abstracts at the ASCO Annual Meeting, Bexion Pharmaceuticals is set to make a significant impact in the oncology space, showcasing its dedication to advancing cancer treatment and improving patient outcomes.